Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Aug 10, 2022
- Accession no.
- 0001493152-22-021919
- Filed
- Aug 10, 2022
- Trade date
- Aug 8-9, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 2 derivative transactions. Open-market sales total $380.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 8, 2022 | Common Stock | MOption exerciseAcquired | +6,943 | $1.74 | +$12,080.82 | 6,943 | Direct | |
| Aug 8, 2022 | Common Stock | SSaleDisposed | −3,989 | $24.39F2 | −$97,291.71 | 2,954 | Direct | |
| Aug 8, 2022 | Common Stock | SSaleDisposed | −2,954 | $24.94F3 | −$73,672.76 | 0 | Direct | |
| Aug 9, 2022 | Common Stock | MOption exerciseAcquired | +8,700 | $1.74 | +$15,138 | 8,700 | Direct | |
| Aug 9, 2022 | Common Stock | SSaleDisposed | −5,909 | $23.84F4 | −$140,870.56 | 2,791 | Direct | |
| Aug 9, 2022 | Common Stock | SSaleDisposed | −2,791 | $24.52F5 | −$68,435.32 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 8, 2022 | Common Stock | MOption exerciseDisposed | −6,943 | $0.00 | $0 | 41,350 | Direct | |
| Aug 9, 2022 | Common Stock | MOption exerciseDisposed | −8,700 | $0.00 | $0 | 32,650 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.80 to $24.75, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.81 to $25.43, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.34 to $24.34, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.345 to $24.70, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary